title: Repeated intracorporeal self-injection: effect on peak systolic velocity and cavernosal artery diameter.
abstract: This work is aimed at evaluating the effect of repeated intracavernosal injection (ICI) self-injection on the peak systolic velocity (PSV) and the diameter of cavernosal arteries. Sixty erectile dysfunction (ED) patients who were positive responders for ICI therapy were studied. Pharmacopenile duplex ultrasonography (PPDU) was carried out before starting ICI and after 10 doses of home therapy in an open-label uncontrolled study. There was significant increase in the cavernosal artery diameter and their PSV before and after injection. Cavernosal arteries diameter before injection in both right and left sides was 0.64+/-0.13 and 0.63+/-0.12 mm at the start and became 0.81+/-0.22 and 0.79+/-0.22 mm respectively at the end with significant differences (P<0.001). Cavernosal arteries diameter after injection in both right and left sides was 1.10+/-0.18 and 1.09+/-0.19 mm at the start and became 1.34+/-0.39 and 1.27+/-0.33 mm respectively at the end with significant differences (P<0.001). PSV at the start was 33.77+/-13.26 and 32.33+/-8.09 cm/s on both right and left sides and became 44.4+/-1.19 and 46.1+/-5.86 cm/s respectively at the end with significant differences (P<0.001). It is concluded that repeated ICI improves arterial erectile response with associated increase in PSV and cavernosal artery diameters.
authors.affiliation: Department of Andrology and Sexology, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: H
authors.initials: H
authors.lastname: Awad
authors.forename: A
authors.initials: A
authors.lastname: El-Karaksy
authors.forename: T
authors.initials: T
authors.lastname: Mostafa
authors.forename: M
authors.initials: M
authors.lastname: Abbas
authors.forename: I I
authors.initials: II
authors.lastname: Kamel
authors.forename: M
authors.initials: M
authors.lastname: Arafa
authors.forename: A
authors.initials: A
authors.lastname: Zeidan
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage; D001158:Arteries / Q000000981:diagnostic imaging / Q000187:drug effects; D001285:Atropine / Q000008:administration & dosage; D001783:Blood Flow Velocity / Q000187:drug effects; D007172:Erectile Dysfunction / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage; D010208:Papaverine / Q000008:administration & dosage*; D010413:Penis / Q000000981:diagnostic imaging / Q000187:drug effects*; D010646:Phentolamine / Q000008:administration & dosage*; D012646:Self Administration; D014463:Ultrasonography; D014665:Vasodilator Agents / Q000008:administration & dosage*
chemical_list: D000317:Adrenergic alpha-Antagonists; D018727:Muscarinic Antagonists; D014665:Vasodilator Agents; D001285:Atropine; D010208:Papaverine; D000527:Alprostadil; D010646:Phentolamine